This phase III trial is evaluating the safety and effectiveness of a targeted adjuvant therapy in patients with stage 2 or 3 non-small cell lung cancer who have had their cancer removed or treated with curative intent.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Eligible patients will be randomised to receive intravenous Durvalumab (Medi4736) or a placebo comparator.
Recruiting Hospitals Read More